keyword
https://read.qxmd.com/read/38352242/heterogeneities-and-impact-profiles-of-early-chronic-obstructive-pulmonary-disease-status-findings-from-the-china-pulmonary-health-study
#21
JOURNAL ARTICLE
Jieping Lei, Ke Huang, Sinan Wu, Jianying Xu, Yongjian Xu, Jianping Zhao, Xiangyan Zhang, Chunxue Bai, Yuanlin Song, Jian Kang, Pixin Ran, Yumin Zhou, Huahao Shen, Fuqiandg Wen, Kewu Huang, Yahong Chen, Wanzhen Yao, Tieying Sun, Yingxiang Lin, Jianguo Zhu, Guangliang Shan, Ting Yang, Chen Wang
BACKGROUND: The prevalence, epidemiological and clinical heterogeneities, and impact profiles of individuals with preserved ratio impaired spirometry (PRISm), pre-COPD, young COPD, and mild COPD in general Chinese population were not known yet. METHODS: Data were obtained from the China Pulmonary Health study (2012-2015), a nationally representative cross-sectional survey that recruited 50,991 adults aged 20 years or older. Definitions of the four early disease status were consistent with the latest publications and the Global Initiative for Chronic Obstructive Lung Disease criteria...
April 2024: The Lancet Regional Health. Western Pacific
https://read.qxmd.com/read/38330975/safety-and-efficacy-of-onradivir-in-adults-with-acute-uncomplicated-influenza-a-infection-a-multicentre-double-blind-randomised-placebo-controlled-phase-2-trial
#22
JOURNAL ARTICLE
Zifeng Yang, Zhengtu Li, Yangqing Zhan, Zhengshi Lin, Zhonghao Fang, Xiaowei Xu, Lin Lin, Haijun Li, Zejun Lin, Changyuan Kang, Jingyi Liang, Shiwei Liang, Yongming Li, Shaoqiang Li, Xinyun Yang, Feng Ye, Nanshan Zhong
BACKGROUND: Onradivir (ZSP1273) is a novel anti-influenza A virus inhibitor. Preclinical studies show that onradivir can inhibit influenza A H1N1 and H3N2 replication and increase the survival rate of infected animals. In this study, we aimed to evaluate the safety and efficacy of three onradivir dosing regimens versus placebo in outpatients with acute uncomplicated influenza A virus infection. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial at 20 clinical sites in China...
February 5, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38310918/hydrocortisone-plus-fludrocortisone-for-community-acquired-pneumonia-related-septic-shock-a-subgroup-analysis-of-the-aprocchss-phase-3-randomised-trial
#23
JOURNAL ARTICLE
Nicholas Heming, Alain Renault, Emmanuelle Kuperminc, Christian Brun-Buisson, Bruno Megarbane, Jean-Pierre Quenot, Shidasp Siami, Alain Cariou, Xavier Forceville, Carole Schwebel, Marc Leone, Jean-Francois Timsit, Benoît Misset, Mohamed Ali Benali, Gwenhael Colin, Bertrand Souweine, Karim Asehnoune, Emmanuelle Mercier, Loïc Chimot, Claire Charpentier, Bruno François, Thierry Boulain, Frank Petitpas, Jean Michel Constantin, Gilles Dhonneur, François Baudin, Alain Combes, Julien Bohé, Jean-François Loriferne, Fabrice Cook, Michel Slama, Olivier Leroy, Gilles Capellier, Auguste Dargent, Tarik Hissem, Rania Bounab, Virginie Maxime, Pierre Moine, Eric Bellissant, Djillali Annane
BACKGROUND: Glucocorticoids probably improve outcomes in patients hospitalised for community acquired pneumonia (CAP). In this a priori planned exploratory subgroup analysis of the phase 3 randomised controlled Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, we aimed to investigate responses to hydrocortisone plus fludrocortisone between CAP and non-CAP related septic shock. METHODS: APROCCHSS was a randomised controlled trial that investigated the effects of hydrocortisone plus fludrocortisone, drotrecogin-alfa (activated), or both on mortality in septic shock in a two-by-two factorial design; after drotrecogin-alfa was withdrawn on October 2011, from the market, the trial continued on two parallel groups...
February 1, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38310914/estimated-health-effects-from-domestic-use-of-gaseous-fuels-for-cooking-and-heating-in-high-income-middle-income-and-low-income-countries-a-systematic-review-and-meta-analyses
#24
JOURNAL ARTICLE
Elisa Puzzolo, Nigel Fleeman, Federico Lorenzetti, Fernando Rubinstein, Yaojie Li, Ran Xing, Guofeng Shen, Emily Nix, Michelle Maden, Rebecca Bresnahan, Rui Duarte, Lydia Abebe, Jessica Lewis, Kendra N Williams, Heather Adahir-Rohani, Daniel Pope
BACKGROUND: Exposure to household air pollution from polluting domestic fuel (solid fuel and kerosene) represents a substantial global public health burden and there is an urgent need for rapid transition to clean domestic fuels. Gas for cooking and heating might possibly affect child asthma, wheezing, and respiratory health. The aim of this review was to synthesise the evidence on the health effects of gaseous fuels to inform policies for scalable clean household energy. METHODS: In this systematic review and meta-analysis, we summarised the health effects from cooking or heating with gas compared with polluting fuels (eg, wood or charcoal) and clean energy (eg, electricity and solar energy)...
February 1, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38309287/first-line-penpulimab-combined-with-paclitaxel-and-carboplatin-for-metastatic-squamous-non-small-cell-lung-cancer-in-china-ak105-302-a-multicentre-randomised-double-blind-placebo-controlled-phase-3-clinical-trial
#25
JOURNAL ARTICLE
Hua Zhong, Shengjie Sun, Jianhua Chen, Ziping Wang, Yanqiu Zhao, Guojun Zhang, Gongyan Chen, Ming Zhou, Jianying Zhou, Yingying Du, Lin Wu, Zhi Xu, Xiaodong Mei, Weidong Zhang, Jingdong He, Jiuwei Cui, Zhihong Zhang, Hui Luo, Weiyou Liu, Meili Sun, Jingxun Wu, Yongchun Shen, Shucai Zhang, Nong Yang, Mengzhao Wang, Junguo Lu, Kai Li, Weirong Yao, Qian Sun, Hongmei Yue, Lin Wang, Sheng Ye, Bin Li, Xibin Zhuang, Yueyin Pan, Min Zhang, Yongqian Shu, Zhiyong He, Lei Pan, Yang Ling, Shengming Liu, Qi Zhang, Shunchang Jiao, Baohui Han
BACKGROUND: Penpulimab is a novel programmed death (PD)-1 inhibitor. This study aimed to establish the efficacy and safety of first line penpulimab plus chemotherapy for advanced squamous non-small-cell lung cancer. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 3 clinical trial enrolled patients with locally advanced or metastatic squamous non-small-cell lung cancer from 74 hospitals in China. Eligible participants were aged 18-75 years, had histologically or cytologically confirmed locally advanced (stage IIIb or IIIc) or metastatic (stage IV) squamous non-small-cell lung cancer, were ineligible to complete surgical resection and concurrent or sequential chemoradiotherapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, did not have previous systemic chemotherapy for locally advanced or metastatic non-small-cell lung cancer, and had one or more measurable lesions according to RECIST (version 1...
January 31, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38272050/individualised-short-course-antibiotic-treatment-versus-usual-long-course-treatment-for-ventilator-associated-pneumonia-regard-vap-a-multicentre-individually-randomised-open-label-non-inferiority-trial
#26
JOURNAL ARTICLE
Yin Mo, Suchart Booraphun, Andrew Yunkai Li, Pornanan Domthong, Gyan Kayastha, Yie Hui Lau, Ploenchan Chetchotisakd, Direk Limmathurotsakul, Paul Anantharajah Tambyah, Ben S Cooper
BACKGROUND: Ventilator-associated pneumonia (VAP) is associated with increased mortality, prolonged hospitalisation, excessive antibiotic use and, consequently, increased antimicrobial resistance. In this phase 4, randomised trial, we aimed to establish whether a pragmatic, individualised, short-course antibiotic treatment strategy for VAP was non-inferior to usual care. METHODS: We did an individually randomised, open-label, hierarchical non-inferiority-superiority trial in 39 intensive care units in six hospitals in Nepal, Singapore, and Thailand...
January 22, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38262428/ceftriaxone-to-prevent-early-ventilator-associated-pneumonia-in-patients-with-acute-brain-injury-a-multicentre-randomised-double-blind-placebo-controlled-assessor-masked-superiority-trial
#27
JOURNAL ARTICLE
Claire Dahyot-Fizelier, Sigismond Lasocki, Thomas Kerforne, Pierre-Francois Perrigault, Thomas Geeraerts, Karim Asehnoune, Raphaël Cinotti, Yoann Launey, Vincent Cottenceau, Marc Laffon, Thomas Gaillard, Matthieu Boisson, Camille Aleyrat, Denis Frasca, Olivier Mimoz
BACKGROUND: Patients with acute brain injury are at high risk of ventilator-associated pneumonia (VAP). The benefit of short-term antibiotic prophylaxis remains debated. We aimed to establish the effect of an early, single dose of the antibiotic ceftriaxone on the incidence of early VAP in patients with severe brain injury who required mechanical ventilation. METHODS: PROPHY-VAP was a multicentre, randomised, double-blind, placebo-controlled, assessor-masked, superiority trial conducted in nine intensive care units in eight French university hospitals...
January 19, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38240784/higher-versus-lower-nasal-continuous-positive-airway-pressure-for-extubation-of-extremely-preterm-infants-in-australia-%C3%A3-clat-a-multicentre-randomised-superiority-trial
#28
RANDOMIZED CONTROLLED TRIAL
Anna M Kidman, Brett J Manley, Rosemarie A Boland, Atul Malhotra, Susan M Donath, Friederike Beker, Peter G Davis, Risha Bhatia
BACKGROUND: Extremely preterm infants often require invasive mechanical ventilation, and clinicians aim to extubate these infants as soon as possible. However, extubation failure occurs in up to 60% of extremely preterm infants and is associated with increased mortality and morbidity. Nasal continuous positive airway pressure (nCPAP) is the most common post-extubation respiratory support, but there is no consensus on the optimal nCPAP level to safely avoid extubation failure in extremely preterm infants...
December 2023: Lancet Child & Adolescent Health
https://read.qxmd.com/read/38237620/morphine-for-treatment-of-cough-in-idiopathic-pulmonary-fibrosis-pacify-cough-a-prospective-multicentre-randomised-double-blind-placebo-controlled-two-way-crossover-trial
#29
JOURNAL ARTICLE
Zhe Wu, Lisa G Spencer, Winston Banya, John Westoby, Veronica A Tudor, Pilar Rivera-Ortega, Nazia Chaudhuri, Ira Jakupovic, Brijesh Patel, Muhunthan Thillai, Alex West, Marlies Wijsenbeek, Toby M Maher, Jacky A Smith, Philip L Molyneaux
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease, with most patients reporting cough. Currently, there are no proven treatments. We examined the use of low dose controlled-release morphine compared with placebo as an antitussive therapy in individuals with idiopathic pulmonary fibrosis. METHODS: The PACIFY COUGH study is a phase 2, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial done in three specialist centres in the UK...
January 15, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38219763/the-effectiveness-of-covid-19-vaccines-to-prevent-long-covid-symptoms-staggered-cohort-study-of-data-from-the-uk-spain-and-estonia
#30
JOURNAL ARTICLE
Martí Català, Núria Mercadé-Besora, Raivo Kolde, Nhung T H Trinh, Elena Roel, Edward Burn, Trishna Rathod-Mistry, Kristin Kostka, Wai Yi Man, Antonella Delmestri, Hedvig M E Nordeng, Anneli Uusküla, Talita Duarte-Salles, Daniel Prieto-Alhambra, Annika M Jödicke
BACKGROUND: Although vaccines have proved effective to prevent severe COVID-19, their effect on preventing long-term symptoms is not yet fully understood. We aimed to evaluate the overall effect of vaccination to prevent long COVID symptoms and assess comparative effectiveness of the most used vaccines (ChAdOx1 and BNT162b2). METHODS: We conducted a staggered cohort study using primary care records from the UK (Clinical Practice Research Datalink [CPRD] GOLD and AURUM), Catalonia, Spain (Information System for Research in Primary Care [SIDIAP]), and national health insurance claims from Estonia (CORIVA database)...
January 11, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38215786/flooding-and-excessive-rainfall-risk-respiratory-health
#31
EDITORIAL
The Lancet Respiratory Medicine
No abstract text is available yet for this article.
January 9, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38190835/advancing-careers-in-critical-care-medicine-the-power-of-sponsorship-and-mentorship
#32
JOURNAL ARTICLE
Francesca Rubulotta
No abstract text is available yet for this article.
January 5, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38185135/risk-factors-for-covid-19-associated-pulmonary-aspergillosis-a-systematic-review-and-meta-analysis
#33
JOURNAL ARTICLE
Francesca Gioia, Laura N Walti, Ani Orchanian-Cheff, Shahid Husain
BACKGROUND: COVID-19-associated pulmonary aspergillosis (CAPA) has been reported to be an emerging and potentially fatal complication of severe COVID-19. However, risk factors for CAPA have not been systematically addressed to date. METHODS: In this systematic review and meta-analysis to identify factors associated with CAPA, we comprehensively searched five medical databases: Ovid MEDLINE; Ovid Embase; the Cochrane Database of Systematic Reviews; the Cochrane Central Register of Controlled Trials; and the WHO COVID-19 Database...
January 4, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38184010/segmentectomy-versus-lobectomy-in-small-sized-peripheral-non-small-cell-lung-cancer-with-radiologically-pure-solid-appearance-in-japan-jcog0802-wjog4607l-a-post-hoc-supplemental-analysis-of-a-multicentre-open-label-phase-3-trial
#34
RANDOMIZED CONTROLLED TRIAL
Aritoshi Hattori, Kenji Suzuki, Kazuya Takamochi, Masashi Wakabayashi, Yuta Sekino, Yasuhiro Tsutani, Ryu Nakajima, Keiju Aokage, Hisashi Saji, Masahiro Tsuboi, Morihito Okada, Hisao Asamura, Kenichi Nakamura, Haruhiko Fukuda, Shun-Ichi Watanabe
BACKGROUND: Although segmentectomy was better than lobectomy in terms of overall survival for patients with non-small-cell lung cancer (NSCLC) with a pure-solid tumour appearance on thin-section CT in the open-label, multicentre, randomised, controlled, phase 3 JCOG0802/WJOG4607L trial, the reasons why segmentectomy was associated with better overall survival were unclear. We aimed to compare the survival, cause of death, and recurrence patterns after segmentectomy versus lobectomy in trial participants with NSCLC with a pure-solid appearance METHODS: We conducted a post-hoc supplemental analysis of the JCO0802/WJOG4607L randomised, controlled, non-inferiority trial for the patients (aged 20-85 years) with small-sized NSCLC with radiologically pure-solid appearance on thin-section CT (≤2 cm, consolidation tumour ratio 1·0)...
February 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38184008/clarithromycin-for-early-anti-inflammatory-responses-in-community-acquired-pneumonia-in-greece-access-a-randomised-double-blind-placebo-controlled-trial
#35
JOURNAL ARTICLE
Evangelos J Giamarellos-Bourboulis, Athanasios Siampanos, Amalia Bolanou, Sarantia Doulou, Nikolaos Kakavoulis, Konstantinos Tsiakos, Sokratis Katopodis, Georgios Schinas, Lamprini Skorda, Zoi Alexiou, Konstantinos Armenis, Paraskevi Katsaounou, George Chrysos, Aikaterini Masgala, Garyphalia Poulakou, Nikolaos Antonakos, Asimina Safarika, Miltiades Kyprianou, Konstantina Dakou, Styliani Gerakari, Ilias C Papanikolaou, Haralampos Milionis, Markos Marangos, George N Dalekos, Vasiliki Tzavara, Karolina Akinosoglou, Eryfilli Hatziaggelaki, Styliani Sympardi, Theano Kontopoulou, Maria Mouktaroudi, Antonios Papadopoulos, Michael S Niederman
BACKGROUND: Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of patients in hospital with community-acquired pneumonia is based on results from observational studies and meta-analyses rather than randomised clinical trials. We investigated if addition of the macrolide clarithromycin to treatment with a β-lactam antibiotic in this population could improve early clinical response-the new regulatory endpoint for community-acquired pneumonia-and explored the possible contribution of modulation of the inflammatory host response to that outcome...
January 3, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38142698/profiling-the-dysregulated-immune-response-in-sepsis-overcoming-challenges-to-achieve-the-goal-of-precision-medicine
#36
REVIEW
Sara Cajander, Matthijs Kox, Brendon P Scicluna, Markus A Weigand, Raquel Almansa Mora, Stefanie B Flohé, Ignacio Martin-Loeches, Gunnar Lachmann, Massimo Girardis, Alberto Garcia-Salido, Frank M Brunkhorst, Michael Bauer, Antoni Torres, Andrea Cossarizza, Guillaume Monneret, Jean-Marc Cavaillon, Manu Shankar-Hari, Evangelos J Giamarellos-Bourboulis, Martin Sebastian Winkler, Tomasz Skirecki, Marcin Osuchowski, Ignacio Rubio, Jesus F Bermejo-Martin, Joerg C Schefold, Fabienne Venet
Sepsis is characterised by a dysregulated host immune response to infection. Despite recognition of its significance, immune status monitoring is not implemented in clinical practice due in part to the current absence of direct therapeutic implications. Technological advances in immunological profiling could enhance our understanding of immune dysregulation and facilitate integration into clinical practice. In this Review, we provide an overview of the current state of immune profiling in sepsis, including its use, current challenges, and opportunities for progress...
December 21, 2023: Lancet Respiratory Medicine
https://read.qxmd.com/read/38142697/adaptive-servo-ventilation-for-sleep-disordered-breathing-in-patients-with-heart-failure-with-reduced-ejection-fraction-advent-hf-a-multicentre-multinational-parallel-group-open-label-phase-3-randomised-controlled-trial
#37
RANDOMIZED CONTROLLED TRIAL
T Douglas Bradley, Alexander G Logan, Geraldo Lorenzi Filho, R John Kimoff, Joaquin Durán Cantolla, Michael Arzt, Stefania Redolfi, Gianfranco Parati, Takatoshi Kasai, Mark E Dunlap, Diego Delgado, Shoichiro Yatsu, Adriana Bertolami, Rodrigo Pedrosa, George Tomlinson, Jose M Marin Trigo, Claudio Tantucci, John S Floras
BACKGROUND: In patients with heart failure and reduced ejection fraction, sleep-disordered breathing, comprising obstructive sleep apnoea (OSA) and central sleep apnoea (CSA), is associated with increased morbidity, mortality, and sleep disruption. We hypothesised that treating sleep-disordered breathing with a peak-flow triggered adaptive servo-ventilation (ASV) device would improve cardiovascular outcomes in patients with heart failure and reduced ejection fraction. METHODS: We conducted a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial of peak-flow triggered ASV in patients aged 18 years or older with heart failure and reduced ejection fraction (left ventricular ejection fraction ≤45%) who were stabilised on optimal medical therapy with co-existing sleep-disordered breathing (apnoea-hypopnoea index [AHI] ≥15 events/h of sleep), with concealed allocation and blinded outcome assessments...
February 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38141633/changes-in-the-global-hospitalisation-burden-of-respiratory-syncytial-virus-in-young-children-during-the-covid-19-pandemic-a-systematic-analysis
#38
JOURNAL ARTICLE
Bingbing Cong, Uğurcan Koç, Teresa Bandeira, Quique Bassat, Louis Bont, Giorgi Chakhunashvili, Cheryl Cohen, Christine Desnoyers, Laura L Hammitt, Terho Heikkinen, Q Sue Huang, Joško Markić, Ainara Mira-Iglesias, Jocelyn Moyes, D James Nokes, Dominique Ploin, Euri Seo, Rosalyn Singleton, Nicole Wolter, Chee Fu Yung, Heather J Zar, Daniel R Feikin, Erin G Sparrow, Harish Nair, You Li
BACKGROUND: The COVID-19 pandemic is reported to have affected the epidemiology of respiratory syncytial virus (RSV), which could have important implications for RSV prevention and control strategies. We aimed to assess the hospitalisation burden of RSV-associated acute lower respiratory infection (ALRI) in children younger than 5 years during the pandemic period and the possible changes in RSV epidemiology from a global perspective. METHODS: We conducted a systematic literature search for studies published between Jan 1, 2020, and June 30, 2022, in MEDLINE, Embase, Global Health, Web of Science, the WHO COVID-19 Research Database, CINAHL, LILACS, OpenGrey, CNKI, WanFang, and CqVip...
December 20, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/38141623/coal-power-plant-pollution-linked-to-deaths-in-the-usa
#39
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
December 20, 2023: Lancet Respiratory Medicine
https://read.qxmd.com/read/38109918/association-of-novel-adult-cough-subclasses-with-clinical-characteristics-and-lung-function-across-six-decades-of-life-in-a-prospective-community-based-cohort-in-australia-an-analysis-of-the-tasmanian-longitudinal-health-study-tahs
#40
JOURNAL ARTICLE
Jingwen Zhang, Caroline J Lodge, E Haydn Walters, Anne B Chang, Dinh S Bui, Adrian J Lowe, Garun S Hamilton, Paul S Thomas, Chamara V Senaratna, Alan L James, Bruce R Thompson, Bircan Erbas, Michael J Abramson, Jennifer L Perret, Shyamali C Dharmage
BACKGROUND: Cough is a common yet heterogeneous condition. Little is known about the characteristics and course of cough in general populations. We aimed to investigate cough subclasses, their characteristics from childhood across six decades of life, and potential treatable traits in a community-based cohort. METHODS: For our analysis of the Tasmanian Longitudinal Health Study (TAHS), a prospective, community-based cohort study that began on Feb 23, 1968, and has so far followed up participants in Tasmania, Australia, at intervals of 10 years from a mean age of 7 years to a mean age of 53 years, we used data collected as part of the TAHS to distinguish cough subclasses among current coughers at age 53 years...
December 15, 2023: Lancet Respiratory Medicine
keyword
keyword
36855
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.